Teachers Advisors LLC acquired a new stake in Abeona Therapeutics Inc. (NASDAQ:ABEO) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 44,354 shares of the biopharmaceutical company’s stock, valued at approximately $284,000. Teachers Advisors LLC owned 0.11% of Abeona Therapeutics as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. State of Wisconsin Investment Board acquired a new position in shares of Abeona Therapeutics in the 2nd quarter valued at about $122,000. Rhumbline Advisers acquired a new position in shares of Abeona Therapeutics in the 2nd quarter valued at about $190,000. Schwab Charles Investment Management Inc. acquired a new position in shares of Abeona Therapeutics in the 2nd quarter valued at about $264,000. Bank of New York Mellon Corp lifted its holdings in shares of Abeona Therapeutics by 125.8% in the 1st quarter. Bank of New York Mellon Corp now owns 41,929 shares of the biopharmaceutical company’s stock valued at $210,000 after buying an additional 23,358 shares during the period. Finally, Essex Investment Management Co. LLC acquired a new position in shares of Abeona Therapeutics in the 2nd quarter valued at about $594,000. 33.36% of the stock is owned by institutional investors and hedge funds.

ABEO has been the subject of several analyst reports. SunTrust Banks, Inc. initiated coverage on Abeona Therapeutics in a report on Wednesday, November 8th. They issued a “buy” rating and a $26.00 price objective for the company. Zacks Investment Research cut Abeona Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, August 16th. BidaskClub cut Abeona Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, August 2nd. Royal Bank Of Canada began coverage on Abeona Therapeutics in a report on Thursday, September 14th. They issued an “outperform” rating and a $23.00 price target for the company. Finally, Cantor Fitzgerald reaffirmed a “buy” rating and issued a $21.00 price target on shares of Abeona Therapeutics in a report on Friday, October 6th. One analyst has rated the stock with a sell rating, one has issued a hold rating and nine have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $22.90.

Shares of Abeona Therapeutics Inc. (NASDAQ:ABEO) opened at $15.40 on Friday. Abeona Therapeutics Inc. has a 52 week low of $4.05 and a 52 week high of $22.75.

Abeona Therapeutics (NASDAQ:ABEO) last posted its quarterly earnings data on Wednesday, November 15th. The biopharmaceutical company reported ($0.13) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.18) by $0.05. Abeona Therapeutics had a negative return on equity of 27.69% and a negative net margin of 2,946.58%. The company had revenue of $0.22 million during the quarter, compared to analyst estimates of $0.22 million. equities analysts anticipate that Abeona Therapeutics Inc. will post -0.7 EPS for the current year.

WARNING: This article was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this article on another website, it was copied illegally and reposted in violation of U.S. & international trademark and copyright legislation. The original version of this article can be accessed at https://www.thecerbatgem.com/2017/11/19/teachers-advisors-llc-takes-284000-position-in-abeona-therapeutics-inc-abeo.html.

About Abeona Therapeutics

Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB).

Institutional Ownership by Quarter for Abeona Therapeutics (NASDAQ:ABEO)

Receive News & Stock Ratings for Abeona Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics Inc. and related stocks with our FREE daily email newsletter.